In its Q2 2026 investor letter, Conestoga Capital Advisors highlighted Bio-Techne Corporation (NASDAQ:TECH) as a performance contributor.
Bio-Techne Corporation (NASDAQ:TECH) is a leader in the life science research market that engages in the manufacturing and selling of life science reagents, instruments, and services
On August 5, 2026, Bio-Techne Corporation (NASDAQ:TECH) closed at $72.00 per share, reflecting a market capitalization of $11.22 billion. Bio-Techne Corporation (NASDAQ:TECH) posted a one-month return of 1.19%, while its shares gained 43.57% over the past 52 weeks. Conestoga Capital Advisors stated the following regarding Bio-Techne Corporation (NASDAQ:TECH) in its Q2 2026 investor letter: “Bio-Techne Corporation (NASDAQ:TECH) develops life science research tools, and diagnostic products used by pharmaceutical, biotechnology, and academic researchers.
The company benefited from growing confidence that several temporary headwinds are beginning to subside, as improving academic funding and continued strength in large pharmaceutical customers offset lingering weakness in emerging biotech. In the quarter, Bio-Techne agreed to an acquisition by Merck KGaA (MRK-GR).” Bio-Techne Corporation (NASDAQ:TECH) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 41 hedge fund portfolios held Bio-Techne Corporation (NASDAQ:TECH) at the end of the first quarter, the same as in the previous quarter.